Tau PET imaging can identify Alzheimer's subtype associated with psychosis: Study

Written By :  Medha Baranwal
Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2022-05-07 03:30 GMT   |   Update On 2022-05-07 03:31 GMT

USA: Results from a recent study in Translational Psychiatry suggests that increase in tau pathology in frontal, medial temporal, and occipital cortices as seen with PET imaging, is associated with psychosis and a more rapid cognitive and functional decline in Alzheimer's disease (AD) patients. Psychosis in Alzheimer's disease is a distinct disease subtype tied to a more rapid illness...

Login or Register to read the full article

USA: Results from a recent study in Translational Psychiatry suggests that increase in tau pathology in frontal, medial temporal, and occipital cortices as seen with PET imaging, is associated with psychosis and a more rapid cognitive and functional decline in Alzheimer's disease (AD) patients. 

Psychosis in Alzheimer's disease is a distinct disease subtype tied to a more rapid illness progression as evident with a astened mortality and increased velocity of f cognitive decline. Previous studies have suggested tau neuropathology to be a possible mediator of the accelerated decline in AD psychosis.

Tau positron emission tomography (PET) neuroimaging gives the opportunity to evaluate tau pathology in-vivo, so that clinical symptomatology can be compared with disease pathology. [18F]-AV1451 (Flortaucipir) is a PET ligand having high affinity for insoluble aired-helical filaments (PHFs) of hyperphosphorylated tau. 

Against the above background, J. J. Gomar, Feinstein Institutes for Medical Research, Manhassett, NY, USA, and colleagues aimed to determine whether the development of psychosis and worsened prognosis in AD is associated with an increased burden of tau pathology that can be identified with tau imaging. 

For this purpose, the researchers identified subjects within the Alzheimer's disease neuroimaging initiative (ADNI) who had [18F]-AV1451 imaging at baseline and became psychotic over the course of the study (N = 17). They were then matched in the ratio of 1:3 for gender, age, and education to subjects who had [18F]-AV1451 imaging at baseline and did not become psychotic (N = 50). Baseline [18F]-AV1451 retention was then compared along with cognitive and functional baseline and longitudinal change, in those who became psychotic over the course of participation in ADNI with those who did not. 

The authors conclude, "the results suggest that increases in tau pathology in frontal, medial temporal, and occipital cortices, visualized with [18F]-AV1451 binding, are associated with psychosis and a more rapid cognitive and functional decline."

Reference:

Gomar, J.J., Tan, G., Halpern, J. et al. Increased retention of tau PET ligand [18F]-AV1451 in Alzheimer's Disease Psychosis. Transl Psychiatry 12, 82 (2022). https://doi.org/10.1038/s41398-022-01850-z

Tags:    
Article Source : Translational Psychiatry

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News